Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Gynaecological Cancers Congress 2022

Clinical trial highlights

ATHENA (GOG-3020/ENGOT-ov45): A randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

Date

18 Jun 2022

Session

Clinical trial highlights

Topics

Tumour Site

Ovarian Cancer

Presenters

Rebecca Kristeleit

Authors

R. Kristeleit

Author affiliations

  • Guys and St Thomas NHS Trust, London/GB

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Live Q&A

Presenter: Susana Banerjee

Session: Clinical trial highlights

Resources:

Webcast

Live Q&A

Presenter: Susana Banerjee

Session: Clinical trial highlights

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.